[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100624825":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":14,"responsibleParty":29,"collaborators":7,"id":33,"slug":7,"hasResults":34,"nctId":35,"briefTitle":36,"officialTitle":37,"acronym":38,"eligibilityCriteria":39,"healthyVolunteers":34,"sex":40,"minAge":41,"maxAge":7,"enrollmentInfo":42,"targetDuration":7,"studyType":45,"phases":7,"briefSummary":46,"conditions":47,"keywords":49,"overallStatus":51,"whyStopped":7,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":61},{"fullName":5,"class":6},"Central Hospital, Nancy, France","OTHER",null,[9],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"Léa JACQUEL, MD, Clinical assistant","CONTACT","+33383153298","l.jacquel2@chru-nancy.fr",[15],{"facility":16,"status":7,"city":17,"state":7,"zip":18,"country":19,"countryCode":20,"cosmosGeoPoint":21,"geoPoint":26,"contacts":27},"Université de Nancy","Vandœuvre-lès-Nancy","54500","France","FR",{"type":22,"coordinates":23},"Point",[24,25],6.17114,48.66115,{"lat":25,"lon":24},[28],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},{"type":30,"investigatorFullName":31,"investigatorTitle":32,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"PRINCIPAL_INVESTIGATOR","JACQUEL Léa","Docteur","100624825",false,"NCT07414667","Primary Sjögren's Syndrome: Impact of Quantitative Anti-Ro52 Antibody Analysis on Patient Prognosis and Stratification (Ro-SjS)","Primary Sjögren's Syndrome: Impact of Quantitative Anti-Ro52 Antibody Analysis on Patient Prognosis and Stratification","Ro-SjS","Inclusion Criteria :\n\n* Age ≥ 18 years at the time of inclusion,\n* Diagnosis of primary Sjögren's syndrome according to the 2016 ACR\u002FEULAR classification criteria,\n* Quantitative measurement of anti-Ro52 antibodies performed as part of routine care, starting from 2020 (date of routine implementation in the laboratory),\n* Documented medical follow-up in the internal medicine department (or other participating department),\n* No objection to participation in research after being informed according to current regulations (record of non-opposition if applicable).\n\nExclusion Criteria\n\n* Presence of another systemic autoimmune connective tissue disease, including systemic lupus erythematosus, systemic sclerosis, autoimmune myositis, rheumatoid arthritis (except nonspecific arthralgia without classification criteria),\n* History of solid organ or bone marrow transplantation,\n* Severe immunosuppression unrelated to Sjögren's syndrome (e.g., HIV infection, ongoing chemotherapy for active hematologic malignancy),\n* Incomplete or non-exploitable clinical or biological data preventing analysis of primary or secondary endpoints,\n* Individuals under legal protection measures (e.g., guardianship).","ALL","18 Years",{"count":43,"type":44},150,"ESTIMATED","OBSERVATIONAL","This study aims to evaluate the prognostic value of quantitative anti-Ro52 antibody levels in patients with primary Sjögren's Syndrome. Anti-Ro52 antibodies are frequently detected in this autoimmune disease, but their specific role in disease stratification, systemic involvement, and long-term outcomes remains unclear. Through a prospective cohort analysis, the investigators will investigate the association between anti-Ro52 titers and clinical phenotypes, including extraglandular manifestations, immunological profiles, and disease progression. The objective is to determine whether quantitative assessment of anti-Ro52 antibodies can serve as a biomarker to refine risk stratification and guide personalized management in primary Sjögren's Syndrome.",[48],"Sjögren´s Syndrome",[50],"Anti-Ro52 antibodies","NOT_YET_RECRUITING","2026-02-12",{"date":54,"type":55},"2026-02-17","ACTUAL",{"date":57,"type":44},"2026-06-01",{"date":59,"type":44},"2028-06-01",{"name":5,"class":6},1]